# Gemini Pharmaceuticals, Inc. - Inspection Records Source: https://www.keypedia.com/companies/gemini-pharmaceuticals-inc/9e83f65c-3863-4ad6-a434-b37d9673ac0f > Inspection records and compliance data for Gemini Pharmaceuticals, Inc. in Commack, New York. Access full analysis and detailed observations. --- ## Details - Name: Gemini Pharmaceuticals, Inc. - FEI Number: 2432926 - City: Commack - State: New York - Country Name: United States - Address Line 1: 87 Modular Ave - Zip Code: 11725 ## Related Documents - [483 - Gemini Pharmaceuticals, Inc. - 2022-07-26](https://www.keypedia.com/records/483/gemini-pharmaceuticals-inc/ece92446-1406-489e-aeac-8758665dd9f7) — source: FDA, date: July 26, 2022 - [FDA Inspection 1175407 - Gemini Pharmaceuticals, Inc. - 2022-07-26](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/92c472bb-08e5-409c-b8ae-8486b86edb42) — classification: No Action Indicated (NAI), source: FDA, date: July 26, 2022 - [FDA Inspection 1175407 - Gemini Pharmaceuticals, Inc. - 2022-07-26](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/e65a779b-d253-4945-bbc8-dfca238ee96d) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 26, 2022 - [FDA Inspection 1064447 - Gemini Pharmaceuticals, Inc. - 2018-08-23](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/75b14ea2-9725-4534-814a-36758a020bba) — classification: No Action Indicated (NAI), source: FDA, date: August 23, 2018 - [EIR - Gemini Pharmaceuticals, Inc. - 2018-02-16](https://www.keypedia.com/records/eir/gemini-pharmaceuticals-inc/1b754bc1-a15c-414b-aeeb-a97dddcbb36c) — source: FDA, date: February 16, 2018 - [483 - Gemini Pharmaceuticals, Inc. - 2018-02-16](https://www.keypedia.com/records/483/gemini-pharmaceuticals-inc/563a968e-94b3-45dd-b4f5-b8039e638982) — source: FDA, date: February 16, 2018 - [FDA Inspection 1041525 - Gemini Pharmaceuticals, Inc. - 2018-02-16](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/5f815dde-5720-44ae-a6e5-ab350f64a85e) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 16, 2018 - [EIR - Gemini Pharmaceuticals, Inc. - 2015-06-30](https://www.keypedia.com/records/eir/gemini-pharmaceuticals-inc/8b9c0f66-00ab-4cd3-88f2-b473544da1a7) — source: FDA, date: June 30, 2015 - [483 - Gemini Pharmaceuticals, Inc. - 2015-06-30](https://www.keypedia.com/records/483/gemini-pharmaceuticals-inc/355d3e31-f50a-4ffb-8c27-5cb4b6411eb3) — source: FDA, date: June 30, 2015 - [FDA Inspection 936886 - Gemini Pharmaceuticals, Inc. - 2015-06-30](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/6d577591-8391-4524-a2b4-21427df5636b) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 30, 2015 - [FDA Inspection 856101 - Gemini Pharmaceuticals, Inc. - 2013-11-08](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/755ecb80-8106-43f2-8f2c-49f8a092e6ac) — classification: No Action Indicated (NAI), source: FDA, date: November 8, 2013 - [FDA Inspection 856101 - Gemini Pharmaceuticals, Inc. - 2013-11-08](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/a0e9984c-d1de-458a-8f0d-9838d2949911) — classification: No Action Indicated (NAI), source: FDA, date: November 8, 2013 - [FDA Inspection 804876 - Gemini Pharmaceuticals, Inc. - 2012-09-07](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/8ccd38c4-b04f-4a2f-a1ab-040379671397) — classification: No Action Indicated (NAI), source: FDA, date: September 7, 2012 - [EIR - Gemini Pharmaceuticals, Inc. - 2011-06-01](https://www.keypedia.com/records/eir/gemini-pharmaceuticals-inc/1cffccbc-7f16-4c74-a844-b67a5fe725ba) — source: FDA, date: June 1, 2011 - [483 - Gemini Pharmaceuticals, Inc. - 2011-06-01](https://www.keypedia.com/records/483/gemini-pharmaceuticals-inc/d3335f63-f681-4529-a490-7f5be013903e) — source: FDA, date: June 1, 2011 - [FDA Inspection 726235 - Gemini Pharmaceuticals, Inc. - 2011-06-01](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/36e1597c-1447-4a34-be98-ec5dcbc2deb5) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 1, 2011 - [EIR - Gemini Pharmaceuticals, Inc. - 2010-03-23](https://www.keypedia.com/records/eir/gemini-pharmaceuticals-inc/2a6f3f3e-9c39-474a-a005-1e8d8500073e) — source: FDA, date: March 23, 2010 - [FDA Inspection 652318 - Gemini Pharmaceuticals, Inc. - 2010-03-23](https://www.keypedia.com/records/fda_inspections/gemini-pharmaceuticals-inc/0dd8aacb-038a-4c9f-8703-2e76055dd836) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 23, 2010 - [EIR - Gemini Pharmaceuticals, Inc. - 2009-02-05](https://www.keypedia.com/records/eir/gemini-pharmaceuticals-inc/3279d636-5970-47f7-8c7a-7260f6323fea) — source: FDA, date: February 5, 2009 ## Related Companies - [Haw Par Healthcare Limited](https://www.keypedia.com/companies/haw-par-healthcare-limited/4624588e-3f62-4c4c-8ea2-297ba6465337) - [ADMA Biologics, Inc](https://www.keypedia.com/companies/adma-biologics-inc/dcb996fb-4a71-44fe-87f1-cfe3979d4182) - [Gadal Laboratories Inc.](https://www.keypedia.com/companies/gadal-laboratories-inc/ab020b2d-bc0c-4731-bc27-f75fc34163d4) - [Abraham J. and Phyllis Katz Cord Blood Foundation](https://www.keypedia.com/companies/abraham-j-and-phyllis-katz-cord-blood-foundation/2665cdeb-06d3-4c71-8c69-e14cc4c81536) - [World Perfumes Inc.](https://www.keypedia.com/companies/world-perfumes-inc/97d75c90-5a60-4810-8ffb-5c48b7fcea9c) - [Products By O2, Inc](https://www.keypedia.com/companies/products-by-o2-inc/20f8ca53-bf8e-4dcc-99fc-7f01df807cb1) - [Coherus Biosciences, Inc.](https://www.keypedia.com/companies/coherus-biosciences-inc/6a6c72fd-1805-48ec-b054-bf371321bdf3) - [Hisamitsu Pharmaceutical Co., Inc.](https://www.keypedia.com/companies/hisamitsu-pharmaceutical-co-inc/274efe17-4e85-4f62-adfa-e2fff02f8ed3) - [scPharmaceuticals Inc.](https://www.keypedia.com/companies/scpharmaceuticals-inc/6cd92625-bd5a-4bc6-85f4-aa96798cceaf) - [Sklar BOV Solutions, Inc.](https://www.keypedia.com/companies/sklar-bov-solutions-inc/bb3c6506-3c30-482d-86a7-4f421dba8efa) ## Related Officers - [investigator](https://www.keypedia.com/people/deborah-j-parris/0763ef7f-992d-412b-8497-4539ed851c03) - [recipient](https://www.keypedia.com/people/mike-andrew-finamore/103ee1c1-0ef0-48ac-898f-5f305b2c44ea) - [recipient](https://www.keypedia.com/people/michael-finamore/82dc9fbf-a474-4744-b219-2e22fe1a8523) - [Consumer Safety Officer at FDA](https://www.keypedia.com/people/alice-s-tsao/b6d72ceb-de7c-413d-b104-cac3b075c170) - [investigator](https://www.keypedia.com/people/thomas-j-mooney/160b0a9e-fd07-48a7-af19-ccf648449bdc) - [company_representative](https://www.keypedia.com/people/andrew-a-finamore/674800e2-39e9-4b38-927d-9419734fd17d)